MX2020004334A - Receptor de celulas t novedoso. - Google Patents
Receptor de celulas t novedoso.Info
- Publication number
- MX2020004334A MX2020004334A MX2020004334A MX2020004334A MX2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A
- Authority
- MX
- Mexico
- Prior art keywords
- tcr
- cell
- clone
- vector
- immunogenic
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 11
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgacion esta relacionada con un receptor de celulas T (TCR) novedoso, en particular al menos una region determinante de complementariedad (CDR) del mismo; una celula T que expresa dicho TCR; un clon que expresa dicho TCR; un vector que codifica dicho TCR; una version soluble de dicho TCR; una composicion farmaceutica o agente inmunogenico o biespecifico o vacuna que comprende dicho TCR, dicha celula, dicho clon o dicho vector; el uso de dicho TCR o dicha celula o dicho clon o dicho vector o dicha composicion farmaceutica o agente inmunogenico o biespecifico o vacuna para tratar cancer; y un metodo para tratar cancer utilizando dicho TCR, dicha celula, dicho clon, dicho vector, dicha composicion farmaceutica, agente inmunogenico, biespecifico o vacuna que comprende dicho TCR.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717578.7A GB201717578D0 (en) | 2017-10-26 | 2017-10-26 | Novel T-cell receptor |
| GBGB1806155.6A GB201806155D0 (en) | 2017-10-26 | 2018-04-16 | Novel t-cell receptor |
| PCT/GB2018/053045 WO2019081902A1 (en) | 2017-10-26 | 2018-10-22 | NEW LYMPHOCYTE RECEPTOR T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004334A true MX2020004334A (es) | 2020-08-03 |
Family
ID=60580240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004334A MX2020004334A (es) | 2017-10-26 | 2018-10-22 | Receptor de celulas t novedoso. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11725039B2 (es) |
| EP (2) | EP3700925B8 (es) |
| JP (1) | JP7289311B2 (es) |
| KR (1) | KR20200078497A (es) |
| CN (1) | CN111278855B (es) |
| AU (2) | AU2018356944A1 (es) |
| BR (1) | BR112020007880A2 (es) |
| CA (1) | CA3077635A1 (es) |
| DK (1) | DK3700925T3 (es) |
| EA (1) | EA202091015A1 (es) |
| ES (1) | ES2907819T3 (es) |
| GB (2) | GB201717578D0 (es) |
| IL (1) | IL274025A (es) |
| MX (1) | MX2020004334A (es) |
| PL (1) | PL3700925T3 (es) |
| SG (1) | SG11202002537WA (es) |
| WO (1) | WO2019081902A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
| IL294302A (en) * | 2020-01-09 | 2022-08-01 | Biomunex Pharmaceuticals | Multispecific antibodies that bind both mait cells and tumor cells |
| KR20210153539A (ko) * | 2020-06-10 | 2021-12-17 | 주식회사 유틸렉스 | Mr1에 결합하는 t-세포 수용체 및 이의 용도 |
| WO2022118043A1 (en) | 2020-12-03 | 2022-06-09 | Enara Bio Limited | Novel protein-ligand complex |
| WO2022248881A1 (en) | 2021-05-28 | 2022-12-01 | Enara Bio Limited | Novel protein-ligand complex |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023002204A1 (en) | 2021-07-21 | 2023-01-26 | Enara Bio Limited | T-cell receptor |
| WO2023106894A1 (ko) * | 2021-12-10 | 2023-06-15 | 주식회사 유틸렉스 | Mr1 제한적 panck t 세포 및 이의 제조방법 |
| WO2023148494A1 (en) | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI714869B (zh) * | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| JP6164759B2 (ja) * | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| CN110462024A (zh) * | 2017-03-07 | 2019-11-15 | 巴塞尔大学 | 用于癌症免疫疗法的mr1限制性t细胞受体 |
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
-
2017
- 2017-10-26 GB GBGB1717578.7A patent/GB201717578D0/en not_active Ceased
-
2018
- 2018-04-16 GB GBGB1806155.6A patent/GB201806155D0/en not_active Ceased
- 2018-10-22 SG SG11202002537WA patent/SG11202002537WA/en unknown
- 2018-10-22 BR BR112020007880-8A patent/BR112020007880A2/pt unknown
- 2018-10-22 PL PL18795783T patent/PL3700925T3/pl unknown
- 2018-10-22 CA CA3077635A patent/CA3077635A1/en active Pending
- 2018-10-22 EA EA202091015A patent/EA202091015A1/ru unknown
- 2018-10-22 EP EP18795783.2A patent/EP3700925B8/en active Active
- 2018-10-22 KR KR1020207011102A patent/KR20200078497A/ko not_active Application Discontinuation
- 2018-10-22 EP EP21214567.6A patent/EP4039700A1/en not_active Withdrawn
- 2018-10-22 ES ES18795783T patent/ES2907819T3/es active Active
- 2018-10-22 JP JP2020543406A patent/JP7289311B2/ja active Active
- 2018-10-22 MX MX2020004334A patent/MX2020004334A/es unknown
- 2018-10-22 DK DK18795783.2T patent/DK3700925T3/da active
- 2018-10-22 AU AU2018356944A patent/AU2018356944A1/en not_active Abandoned
- 2018-10-22 CN CN201880069546.9A patent/CN111278855B/zh active Active
- 2018-10-22 WO PCT/GB2018/053045 patent/WO2019081902A1/en unknown
-
2020
- 2020-04-19 IL IL274025A patent/IL274025A/en unknown
- 2020-04-24 US US16/858,082 patent/US11725039B2/en active Active
-
2021
- 2021-01-20 US US17/153,329 patent/US11078252B2/en active Active
-
2024
- 2024-04-26 AU AU2024202735A patent/AU2024202735A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091015A1 (ru) | 2020-07-17 |
| JP2021500406A (ja) | 2021-01-07 |
| ES2907819T3 (es) | 2022-04-26 |
| BR112020007880A2 (pt) | 2020-10-27 |
| AU2018356944A1 (en) | 2020-04-16 |
| JP7289311B2 (ja) | 2023-06-09 |
| CN111278855B (zh) | 2024-04-02 |
| AU2024202735A1 (en) | 2024-05-30 |
| GB201717578D0 (en) | 2017-12-13 |
| GB201806155D0 (en) | 2018-05-30 |
| DK3700925T3 (en) | 2022-04-04 |
| EP3700925A1 (en) | 2020-09-02 |
| KR20200078497A (ko) | 2020-07-01 |
| SG11202002537WA (en) | 2020-05-28 |
| CA3077635A1 (en) | 2019-05-02 |
| IL274025A (en) | 2020-06-30 |
| PL3700925T3 (pl) | 2022-05-02 |
| EP3700925B1 (en) | 2021-12-29 |
| CN111278855A (zh) | 2020-06-12 |
| EP4039700A1 (en) | 2022-08-10 |
| EP3700925B8 (en) | 2022-02-16 |
| US20210147506A1 (en) | 2021-05-20 |
| WO2019081902A1 (en) | 2019-05-02 |
| US11725039B2 (en) | 2023-08-15 |
| US20200369742A1 (en) | 2020-11-26 |
| US11078252B2 (en) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004334A (es) | Receptor de celulas t novedoso. | |
| PH12019500436A1 (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| CO2019001114A2 (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
| CO2018005695A2 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
| MX2017015473A (es) | Tratamiento contra el cancer por manipulacion de la microflora comensal. | |
| CO2017001558A2 (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| BR112017022845A2 (pt) | neoepítopos de câncer | |
| MX2017007321A (es) | Terapias de combinacion. | |
| PE20161209A1 (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma | |
| ECSP22057324A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| BR112018011622A2 (pt) | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae | |
| CO2017008148A2 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| UY36961A (es) | Receptores celulares universales programables y métodos para usar los mismos | |
| WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
| DOP2017000219A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| IN2014MU00303A (es) | ||
| AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| MX2020005495A (es) | Anticuerpo anti-vista y uso del mismo. |